Faster heart rate (HR) has been associated with all-cause mortality, sudden death, and other adverse outcomes in the general population and in patients with heart disease. The relationship between intrinsic (unpaced) HR, continuously measured by an implanted device, and clinical outcomes was assessed in a large implantable cardioverterdefibrillator population. In these subjects, higher HR was associated with greater risk of death or heart failure hospitalization, with those patients exhibiting a mean HR Ͼ90 bpm experiencing almost a 4-fold difference in events compared with those patients with mean HR Ͻ75 bpm. For patients with implantable cardioverter-defibrillators, HR data can predict outcomes in patients with implantable cardioverterdefibrillators. ␤-Blockers appear to reduce events in a direct relationship to HR. Access to HR trends in patients with implantable cardioverter-defibrillators may assist clinical decision making. HR remains an underutilized, but easily determined, and important clinical predictor in this population. See p 2040.
Outcomes of Patients With Acute Type A Aortic Intramural Hematoma
Aortic intramural hematoma (IMH) is increasingly recognized as a unique disease entity with pathological and clinical features differing from those of classic aortic dissection. However, the best treatment of IMH, especially in cases involving the ascending aorta, remains uncertain. We assessed the outcomes of our institutional policy of urgent surgery for unstable type A IMH patients and initial medical treatment for stable patients with surgery for subsequent complications. Type A IMH occurred in 101 patients (28%) admitted with a type A acute aortic syndrome. IMH patients were older than those with aortic dissection and, according to our institutional policy, had less urgent surgery than those with aortic dissection (15.8% versus 87.5%; PϽ0.001). The hospital mortality rate and subsequent longer-term mortality for type A IMH was similar to that for patients with aortic dissection treated with surgery. However, adverse clinical events, such as early sudden death or later progression to aortic dissection, were not uncommon with medical treatment alone. An initial aortic diameter Ͼ55 mm and hematoma thickness Ͼ16 mm were associated with these adverse events and may identify patients with IMH who would benefit from early elective surgery. Type A IMH is a unique disease entity with more favorable response to medical treatment than classic aortic dissection. Risk stratification of IMH based on aortic diameter and hematoma thickness to determine those who should have early surgery requires further testing. See p 2046.
Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease
The clinical importance of the early identification and treatment of peripheral arterial disease (PAD) as a manifestation of generalized atherosclerosis is increasingly being acknowledged. However, differences in risk between the asymptomatic and symptomatic manifestations are less clear. Thus, the aim of this study was to compare the risk for all-cause death and vascular events in elderly individuals with asymptomatic PAD (evidenced by low ankle brachial index) and symptomatic PAD in the primary care setting. We found an alarmingly high prevalence of PAD in the primary care setting (12.2% asymptomatic, 8.7% symptomatic). The composite end point of all-cause mortality or severe cardiac, cerebral, or peripheral vascular events occurred in 27.2 (no PAD), 60.4 (asymptomatic PAD), and 104.7 (symptomatic PAD) cases per 1000 patient-years. Thus, asymptomatic PAD diagnosed through routine screening in the offices of primary care physicians carries a high mortality and vascular event risk, which, in cases of all-cause mortality, is not substantially lower than that of symptomatic PAD. This justifies the routine use of ankle brachial index measurements to identify patients who are at high risk for premature death and vascular events. Measurement of ankle brachial index at baseline provides prognostic information that cannot be derived from conventional risk factors alone. In terms of treatment (ie, secondary prevention), the current American Heart Association/American College of Cardiology guidelines or Transatlantic Inter-Society Consensus II guidelines on PAD do not differentiate between asymptomatic and symptomatic PAD patients, and our results corroborate this approach. See p 2053.
A Common Variant at 9p21 Is Associated With Sudden and Arrhythmic Cardiac Death
Sudden cardiac death (SCD) results in 250 000 to 400 000 deaths in the United States annually. Although coronary heart disease is recognized to be a potent risk factor and an acute mechanism for SCD, risk in individuals is poorly estimated, and improved risk prediction is needed. Given the aggregation of SCD within families, we sought to identify genetic factors associated with SCD risk in cases and controls of European ancestry drawn from 6 National Institutes of Health-funded prospective cohorts. We tested for an association between SCD and a common polymorphism, rs10757274, at the 9p21 locus, which has been robustly associated with coronary artery disease. We found that the G allele associated in prior studies with coronary artery disease was associated with a 29% increased risk of SCD per allele copy after adjustment for cardiovascular and lifestyle risk factors (Pϭ0.003). This finding suggests that genetic factors that contribute to coronary artery disease also contribute to SCD risk. It also raises the possibility that the development of a genetic risk profile made up of multiple SCD variants could ultimately improve risk prediction for a lethal and poorly predicted disease. See p 2062.
Prognostic Significance of Delayed-Enhancement Magnetic Resonance Imaging: Survival of 857 Patients With and Without Left Ventricular Dysfunction
Delayed-enhancement magnetic resonance imaging (DE-MRI) is increasingly being used for myocardial variability assessment because it is reproducible, has high spatial and contrast resolution, and can be performed without exposing patients to ionizing radiation. To date, there are only a few reports on the prognostic value of DE-MRI. In the present study, a total of 857 patients who underwent DE-MRI were followed up for a median of 4.4 years. The primary end point was composite all-cause mortality and cardiac transplantation. The degree of DE was assessed qualitatively and was expressed as the scar index. We found that the presence of DE predicted worse transplant-free survival. Scar index was a significant independent predictor of death/cardiac transplantation even after adjustment for traditional prognosticators. In patients with preserved systolic function (ejection fraction Ն50%), those with DE had poor outcomes, similar to patients with systolic dysfunction and no DE. 
Enhancement of Myocardial Regeneration Through Genetic Engineering of Cardiac Progenitor Cells Expressing Pim-1 Kinase
A revolution in the treatment of heart disease has begun, initiated by stem cell-mediated myocardial regeneration. Despite initial enthusiasm, multiple experimental and clinical studies indicate that present-day stem cell-based myogenesis and regeneration approaches fall short of the efficacy desired for reconstitution of myocardium after cardiomyopathic injury. Three significant problems to surmount are poor initial survival of the donated cell population, the number of cells required to mediate reparative processes, and limited engraftment and persistence over time. Therefore, engineering stem cells to enhance their regenerative capacity by increasing their survival, proliferation, and persistence could provide drastic improvements in both cardiac structure and function. Toward that goal, we compared cardiac progenitor cells engineered to overexpress Pim-1, a prosurvival and proproliferation kinase, with unmodified cardiac progenitor cells to assess potential long-term benefits in an experimental infarction model. Results showed that long-term structural and functional benefits were gained only through the use of cardiac progenitor cells expressing Pim-1. Increased de novo formation of both myocardium and vascular structures was observed with the Pim-1-engineered cells relative to control cells. Furthermore, the Pim-1-engineered cells persisted for Ͼ8 months in the recipient heart. Thus, our data demonstrate that Pim-1-mediated cellular reprogramming demonstrably enhances myocardial repair and regeneration while using fewer cells than typically required for such interventions, offering a novel strategy for cellular cardiomyoplasty that is superior to current treatment modalities. See p 2077.
Human C-Reactive Protein Does Not Promote Atherosclerosis in Transgenic Rabbits
Despite the clinical importance of C-reactive protein (CRP) as a potential marker for cardiovascular diseases, the lack of an appropriate animal model has made it difficult to determine whether CRP is merely a marker or is an active mediator in the pathogenesis of atherosclerosis. In past years, studies with the use of transgenic mice expressing either human or rabbit CRP have generated quite controversial and contradictory results. In fact, mice are not appropriate for evaluation of CRP pathophysiology because CRP in mice is not functional in terms of complement activation. In the present study, we have generated novel transgenic rabbits expressing human CRP and documented that human CRP does not affect aortic or coronary atherosclerosis lesion formation in human CRP-transgenic rabbits. Taken together, our data suggest that CRP may not be a contributor of human atherosclerosis. See p 2088.
Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux
Individuals with diabetes mellitus have an increased risk of cardiovascular disease and exhibit platelet hyperreactivity, increasing their resistance to antithrombotic therapies such as aspirin and clopidogrel. As a consequence, more potent antiplatelet therapeutic strategies are increasingly being used to reduce thrombotic complications in diabetes mellitus; however, these approaches have minimal impact on atherosclerotic lesions themselves, leading to persistent plaque instability. The studies presented here demonstrate the effectiveness of a single infusion of reconstituted high-density lipoprotein (HDL) in attenuating the reactivity of platelets from individuals with diabetes mellitus. Furthermore, these studies suggest that platelet hyperreactivity associated with cholesterol accumulation in platelet membranes can be reversed by reconstituted HDL through cholesterol depletion and disruption of lipid rafts. The greater platelet inhibitory properties of reconstituted HDL compared with native HDL suggest that agents that increase pre-␤-HDL particles would have the greatest efficacy with respect to reducing platelet reactivity. Investigations to determine whether reconstituted HDL infusions or long-term HDL-raising agents confer additional benefits to current antithrombotic agents without adversely affecting hemostasis are required. The present findings add a new dimension to the known antiatherosclerotic actions of reconstituted HDL to provide a rationale for HDL-raising therapies as novel antithrombotic agents. See p 2095.
